Primary completion· ClinicalTrials.gov
Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs
Atezolizumab History and Updates
250 events · 2005 – present
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
109
FDA Approvals
2
Label Revisions
2,482
Trial Milestones
10
Pivotal Publications
Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-07-17Download chart as PNG
This page tracks every FDA action, clinical trial milestone, and major publication for Atezolizumab since 2005, drawn from openFDA, ClinicalTrials.gov, and PubMed.
All published updates (114)
2026
- Results postedAtezolizumab NSCLC Trial Terminated; Adverse Event Counts Posted· Jun 10, 2026
- Results postedAtezolizumab + Tiragolumab Phase 3 NSCLC Trial Shows Similar Efficacy to…· Jun 3, 2026
- Results postedAtezolizumab Combo in NSCLC Trial Shows Shorter PFS and OS vs. Pembrolizumab· Jun 3, 2026
- FDA approval (supplemental)Tecentriq (Atezolizumab) Receives FDA Supplemental Efficacy Approval· May 15, 2026
- FDA approval (supplemental)Tecentriq Hybreza (Atezolizumab) Receives FDA Supplemental Efficacy Approval· May 15, 2026
- Results postedAtezolizumab Combination Extends OS in Malignant Pleural Mesothelioma· May 14, 2026
- Results postedAtezolizumab Combos for NSCLC Post-Targeted Therapy Show Similar PFS· May 12, 2026
- Results postedAtezolizumab Trial for NSCLC Shows Varied Objective Response Rates Across…· May 12, 2026
- Results postedAtezolizumab Combos for EGFR-mutant NSCLC Post-TKI Show Median PFS up to 7.6…· May 12, 2026
- Results postedAtezolizumab + Tiragolumab Shows Improved ORR, PFS, OS in SCCHN Trial· May 5, 2026
- Results postedAtezolizumab Combination Therapies Show Varied pCR in Stage III Melanoma· May 4, 2026
- Results postedAtezolizumab Phase 2 Trial Results Posted for Metastatic Prostate Cancer· Apr 24, 2026
- Results postedAtezolizumab + CAPOX Outperforms Triple Therapy in Gastric Carcinoma ORR· Apr 15, 2026
- Results postedAtezolizumab Combination Improves DFS in Stage III dMMR Colon Cancer· Apr 14, 2026
- Results postedAtezolizumab + Tiragolumab Improves Esophageal Cancer PFS and OS· Apr 9, 2026
- Results postedAtezolizumab Trial Results Posted for Locally Advanced Urothelial Carcinoma· Mar 20, 2026
- Results postedAtezolizumab: Plinabulin Combination Trial Results Posted for Advanced Cancers· Mar 18, 2026
- Results postedAtezolizumab + Tiragolumab in NSCLC Shows 71.4% MPR in PD-L1 High Cohort· Mar 11, 2026
- Primary completionAtezolizumab Trial for ES-SCLC Reaches Primary Completion· Feb 28, 2026
- Results postedAtezolizumab Trial Results Posted for Triple Negative Breast Cancer· Feb 17, 2026
- Results postedAtezolizumab Trial for NSCLC with Brain Metastases Terminated Early· Jan 22, 2026
- Results postedAtezolizumab in Triple-Negative Breast Cancer: Window Strategy Shows No…· Jan 12, 2026
- Pivotal publicationAtezolizumab + FOLFOX for Stage III Colon Cancer Trial Data Published· Jan 1, 2026
2025
- Results postedAtezolizumab Shows Improved PFS in HER2+ Metastatic Breast Cancer· Dec 30, 2025
- Primary completionAtezolizumab Phase 3 Trial for NSCLC Reaches Primary Completion· Dec 30, 2025
- Primary completionAtezolizumab Phase 3 NSCLC Trial Completes Primary Data Collection· Dec 30, 2025
- Results postedAtezolizumab + Lurbinectedin Improves PFS, OS in ES-SCLC Maintenance· Dec 29, 2025
- Results postedAtezolizumab + Nab-Paclitaxel in PD-L1+ TNBC: 27.0 Months Median OS· Dec 26, 2025
- Results postedAtezolizumab/Cabozantinib Combo Improves PFS in mCRPC Trial· Dec 18, 2025
- Primary completionAtezolizumab Trial for NSCLC Completes Primary Phase 3 Study· Dec 16, 2025
- Results postedAtezolizumab Plus Bevacizumab Shows Organ-Specific Responses in Advanced HCC· Dec 12, 2025
- Results postedAtezolizumab/Cabozantinib Combo Improves PFS in Advanced HCC Trial· Dec 11, 2025
- Results postedAtezolizumab Plus Bevacizumab Shows 11.3-Month PFS in First-Line NSCLC· Dec 4, 2025
- FDA approval (supplemental)FDA Approves Tecentriq Hybreza (atezolizumab) Supplemental Efficacy Application· Nov 24, 2025
- Results postedAtezolizumab Combinations Show Varied ORR in Metastatic Pancreatic Cancer· Nov 21, 2025
- Results postedAtezolizumab Plus Chemo Shows No Significant OS Improvement in Recurrent TNBC· Nov 12, 2025
- Results postedAtezolizumab Triplets Show Improved Response, PFS in HR+/HER2- Breast Cancer· Nov 10, 2025
- Results postedAtezolizumab Combination Improves ORR and PFS in Extensive-Stage SCLC· Oct 29, 2025
- Results postedAtezolizumab Cancer Digital Health Solutions Trial Terminated· Oct 22, 2025
- Results postedAtezolizumab Trial for High-Risk Skin Cancers Terminated· Oct 22, 2025
- Results postedAtezolizumab + Tiragolumab Shows No Significant Benefit in ES-SCLC· Oct 22, 2025
- Results postedAtezolizumab + Abemaciclib in mCRPC: Mixed PFS and ORR Results· Oct 2, 2025
- FDA approval (supplemental)Tecentriq (Atezolizumab) Secures FDA Supplemental Efficacy Approval· Oct 2, 2025
- FDA approval (supplemental)Tecentriq Hybreza Supplemental Application Approved by FDA for Efficacy· Oct 2, 2025
- Primary completionAtezolizumab Phase 3 Trial for Resectable NSCLC Completes Primary Data…· Oct 1, 2025
- Results postedAtezolizumab + Bevacizumab Shows 20.76-Month OS in Unresectable HCC· Sep 22, 2025
- Results postedAtezolizumab Combo Shows 50% pCR in Head & Neck Squamous Cell Carcinoma· Sep 15, 2025
- Primary completionAtezolizumab Trial for HR+ HER2- Breast Cancer Completes Phase 3 Study· Sep 12, 2025
- Primary completionAtezolizumab Trial for Metastatic Cervical Carcinoma Completes Primary Phase· Aug 31, 2025
- Results postedAtezolizumab + Chemo Improves Response in Prior-Treated NSCLC· Aug 27, 2025
- Results postedAtezolizumab Combination Trial for Advanced Solid Tumors Terminated· Aug 20, 2025
- Results postedAtezolizumab Combination Trial Reports 15.57-Month DOR in Metastatic Breast…· Aug 8, 2025
- Results postedAtezolizumab + Tiragolumab Combo Shows Lower Pathologic Response in Melanoma· Jul 18, 2025
- Results postedAtezolizumab with 50 Gy Radiotherapy for Head and Neck Cancer Shows DLTs· Jul 15, 2025
- Primary completionAtezolizumab Trial for High-Risk Bladder Cancer Reaches Primary Completion· Jun 30, 2025
- Primary completionAtezolizumab Phase 3 Trial for MIBC Reaches Primary Completion· Jun 15, 2025
- Results postedAtezolizumab Plus Chemoradiation Lacks OS Benefit in Limited Stage SCLC· Jun 12, 2025
- Results postedAtezolizumab Combination Trial for Endometrial Cancer Posts ORR Data· May 30, 2025
- Results postedAtezolizumab Shows Numerically Longer Overall Survival in ES-SCLC Trial· May 30, 2025
- Results postedAtezolizumab + Cobimetinib Trial Results Posted for Rare Tumors· May 28, 2025
- Primary completionAtezolizumab Phase 3 Trial for NSCLC Reaches Primary Completion· May 27, 2025
- Results postedAtezolizumab Triple Therapy Shows Longer PFS vs Dual in Biliary Tract Cancer· May 23, 2025
- Results postedAtezolizumab Combination Trial for Solid Tumors Posts Safety Results· May 21, 2025
- Results postedAtezolizumab + Bevacizumab Shows 24.8-Month OS in Unresectable HCC· May 8, 2025
- Primary completionAtezolizumab Hepatocellular Carcinoma Trial Reaches Primary Completion· May 8, 2025
- Results postedAtezolizumab + Chemotherapy in Urothelial Carcinoma Shows 48.5% ORR· Apr 24, 2025
- Results postedAtezolizumab Combination Therapy Shows Dose-Limiting Toxicities in Urothelial…· Apr 9, 2025
- Results postedAtezolizumab Combination Trial for Advanced Malignancies Posts Phase 1 Safety…· Apr 2, 2025
- Results postedAtezolizumab Neo-DIANA Trial for EGFR NSCLC Terminated Early· Apr 2, 2025
- Results postedAtezolizumab Context: Metastatic NSCLC Study Results Posted· Mar 30, 2025
- Results postedAtezolizumab Improves Disease-Free Survival in Adjuvant NSCLC, Especially PD-L1+· Mar 30, 2025
- Results postedAtezolizumab Combo Trial for Advanced RCC Posts Phase 2 Results, Terminated· Mar 20, 2025
- Results postedAtezolizumab + BNT411 Trial for Solid Tumors Posts Safety Data· Mar 18, 2025
- Primary completionAtezolizumab Trial for Recurrent Ovarian Carcinoma Reaches Primary Completion· Mar 11, 2025
- Results postedAtezolizumab Triplet Improves PFS, OS in Recurrent Ovarian Cancer· Mar 4, 2025
- Results postedAtezolizumab Intermittent Therapy Shows Sustained Response in Urothelial…· Feb 25, 2025
- Results postedAtezolizumab Combination Shows Improved Response in Cervical Cancer Trial· Feb 7, 2025
- Primary completionAtezolizumab Improves Disease-Free Survival in Stage III Colon Cancer· Feb 4, 2025
- Pivotal publicationAtezolizumab Plus Zanzalintinib Phase 3 Trial vs Regorafenib in Refractory…· Jan 1, 2025
- Pivotal publicationAtezolizumab: Adjuvant Early TNBC Trial Results Published· Jan 1, 2025
- Pivotal publicationAtezolizumab: IMforte Study on ES-SCLC Maintenance Therapy Published· Jan 1, 2025
- Pivotal publicationAtezolizumab Trial Results Published for High-Risk Head and Neck SCC· Jan 1, 2025
- Pivotal publicationAtezolizumab Adjuvant Therapy for ctDNA-Positive MIBC Published in NEJM· Jan 1, 2025
2024
- FDA approvalTecentriq Hybreza (Atezolizumab) Receives FDA Approval as New Dosage Form· Sep 12, 2024
- Primary completionAtezolizumab + Lurbinectedin Improves PFS and OS in ES-SCLC Maintenance· Jul 29, 2024
- Primary completionAtezolizumab in HER2+ Metastatic Breast Cancer Shows Improved PFS· Apr 30, 2024
- Primary completionAtezolizumab Phase 3 for LS-SCLC: No Significant OS or PFS Improvement· Apr 21, 2024
- Pivotal publicationAtezolizumab BEATcc Trial Results Published for Metastatic Cervical Cancer· Jan 1, 2024
2023
- Primary completionAtezolizumab Extends Median OS by 2.4 Months in Malignant Pleural Mesothelioma· Sep 1, 2023
- Pivotal publicationAtezolizumab Plus Bevacizumab vs. Surveillance in High-Risk HCC Published· Jan 1, 2023
- Pivotal publicationAtezolizumab plus Cabozantinib vs. Monotherapy for Renal Cell Carcinoma· Jan 1, 2023
- Pivotal publicationAtezolizumab Monotherapy vs Chemotherapy for NSCLC Ineligible for Platinum· Jan 1, 2023
2022
- FDA approval (supplemental)Tecentriq (Atezolizumab) Receives FDA Supplemental Efficacy Approval· Dec 9, 2022
- FDA approval (supplemental)Tecentriq (Atezolizumab) Receives FDA Supplemental Efficacy Approval· Dec 2, 2022
2021
- FDA approval (supplemental)Tecentriq (Atezolizumab) Receives FDA Supplemental Efficacy Approval· Oct 15, 2021
- FDA approval (supplemental)Tecentriq (Atezolizumab) FDA Approves Supplemental Efficacy Application· Oct 6, 2021
- FDA approval (supplemental)Tecentriq (Atezolizumab) Receives FDA Supplemental Efficacy Approval· Apr 13, 2021
- FDA approval (supplemental)Atezolizumab (Tecentriq) Receives Supplemental FDA Approval for Efficacy· Feb 17, 2021
2020
- FDA approval (supplemental)Tecentriq (Atezolizumab) Gains FDA Supplemental Efficacy Approval· Dec 18, 2020
- FDA approval (supplemental)Tecentriq (Atezolizumab) Receives Supplemental Efficacy Approval from FDA· Sep 30, 2020
- FDA approval (supplemental)Atezolizumab (Tecentriq) Receives Supplemental FDA Approval for Efficacy· Jul 30, 2020
- FDA approval (supplemental)Tecentriq (Atezolizumab) Receives FDA Supplemental Efficacy Approval· May 29, 2020
- FDA approval (supplemental)Tecentriq (Atezolizumab) Receives FDA Supplemental Efficacy Approval· May 18, 2020
2019
- FDA approval (supplemental)Atezolizumab (Tecentriq) Receives Supplemental FDA Efficacy Approval· Dec 3, 2019
- FDA approval (supplemental)Tecentriq (Atezolizumab) Receives Supplemental FDA Approval for Efficacy· May 6, 2019
- FDA approval (supplemental)Atezolizumab (Tecentriq) Receives FDA Supplemental Efficacy Approval· Mar 18, 2019
- FDA approval (supplemental)Tecentriq (Atezolizumab) Receives FDA Supplemental Efficacy Approval· Mar 8, 2019
2018
- FDA approval (supplemental)Tecentriq (Atezolizumab) Receives FDA Supplemental Efficacy Approval· Dec 6, 2018
- FDA approval (supplemental)Tecentriq (Atezolizumab) Receives FDA Approval for Efficacy Supplemental…· Jul 2, 2018
- FDA approval (supplemental)Atezolizumab (Tecentriq) Receives FDA Supplemental Efficacy Approval· Jun 19, 2018
- FDA approval (supplemental)Tecentriq (Atezolizumab) Receives FDA Supplemental Approval for Efficacy· Jun 14, 2018
- FDA approval (supplemental)FDA approves Tecentriq (Atezolizumab) supplemental efficacy application· Apr 30, 2018
2017
- FDA approval (supplemental)Tecentriq (Atezolizumab) Receives FDA Supplemental Efficacy Approval· Apr 17, 2017
2016
- FDA approvalTecentriq (Atezolizumab) Receives Initial FDA Approval as New Molecular Entity· May 18, 2016
Upcoming & expected milestones
Primary completion· ClinicalTrials.gov
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin Americ
Trial started· ClinicalTrials.gov
DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer
Primary completion· ClinicalTrials.gov
LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients
Trial started· ClinicalTrials.gov
Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
Primary completion· ClinicalTrials.gov
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
Primary completion· ClinicalTrials.gov
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
Trial started· ClinicalTrials.gov
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
Primary completion· ClinicalTrials.gov
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Primary completion· ClinicalTrials.gov
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
Primary completion· ClinicalTrials.gov
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Trial started· ClinicalTrials.gov
A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
Primary completion· ClinicalTrials.gov
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
Primary completion· ClinicalTrials.gov
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Primary completion· ClinicalTrials.gov
Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer
Primary completion· ClinicalTrials.gov
Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC
Primary completion· ClinicalTrials.gov
Perioperative Immunotherapy for NSCLC (ECTOP-1030)
Primary completion· ClinicalTrials.gov
Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER
Trial started· ClinicalTrials.gov
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
Primary completion· ClinicalTrials.gov
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Smal
Primary completion· ClinicalTrials.gov
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Adva
Primary completion· ClinicalTrials.gov
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
Primary completion· ClinicalTrials.gov
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
Primary completion· ClinicalTrials.gov
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Primary completion· ClinicalTrials.gov
A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the T
Primary completion· ClinicalTrials.gov
ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation
Primary completion· ClinicalTrials.gov
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Primary completion· ClinicalTrials.gov
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extens
Primary completion· ClinicalTrials.gov
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanc
Primary completion· ClinicalTrials.gov
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Primary completion· ClinicalTrials.gov
Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer
Primary completion· ClinicalTrials.gov
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-
Primary completion· ClinicalTrials.gov
The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)
Primary completion· ClinicalTrials.gov
Trial of INI-4001 in Patients With Advanced Solid Tumours
Primary completion· ClinicalTrials.gov
Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma
Primary completion· ClinicalTrials.gov
Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
Primary completion· ClinicalTrials.gov
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Primary completion· ClinicalTrials.gov
A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
Primary completion· ClinicalTrials.gov
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid M
Primary completion· ClinicalTrials.gov
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (N
Primary completion· ClinicalTrials.gov
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage
Primary completion· ClinicalTrials.gov
Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
Primary completion· ClinicalTrials.gov
Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)
Primary completion· ClinicalTrials.gov
Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer
Primary completion· ClinicalTrials.gov
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Primary completion· ClinicalTrials.gov
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Anothe
Primary completion· ClinicalTrials.gov
Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblas
Primary completion· ClinicalTrials.gov
Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
Primary completion· ClinicalTrials.gov
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Primary completion· ClinicalTrials.gov
A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas
Past events
2026
Trial registered· ClinicalTrials.gov
A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
Primary completion· ClinicalTrials.gov
PLATFORM Study of Precision Medicine for Rare Tumors
Primary completion· ClinicalTrials.gov
Safety and Efficacy of NK510 to Treat NSCLC
Primary completion· ClinicalTrials.gov
SIRT and Peri-immunotherapy : a New Concept
Primary completion· ClinicalTrials.gov
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
Primary completion· ClinicalTrials.gov
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of
Primary completion· ClinicalTrials.gov
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
Primary completion· ClinicalTrials.gov
Atezolizumab for Idiopathic Pulmonary Fibrosis
Primary completion· ClinicalTrials.gov
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanc
Primary completion· ClinicalTrials.gov
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC
Primary completion· ClinicalTrials.gov
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated Wit
Primary completion· ClinicalTrials.gov
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
Primary completion· ClinicalTrials.gov
Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
Primary completion· ClinicalTrials.gov
Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus
Primary completion· ClinicalTrials.gov
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
Primary completion· ClinicalTrials.gov
A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin Americ
Primary completion· ClinicalTrials.gov
DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab
Trial started· ClinicalTrials.gov
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
Results posted· ClinicalTrials.gov
LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC
Results posted· ClinicalTrials.gov
A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Pa
Trial registered· ClinicalTrials.gov
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
Results posted· ClinicalTrials.gov
A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
Primary completion· ClinicalTrials.gov
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locall
Primary completion· ClinicalTrials.gov
Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Tre
Primary completion· ClinicalTrials.gov
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
Results posted· ClinicalTrials.gov
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
Results posted· ClinicalTrials.gov
A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lun
Trial started· ClinicalTrials.gov
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AAS
Primary completion· ClinicalTrials.gov
Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)
Results posted· ClinicalTrials.gov
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cel
Results posted· ClinicalTrials.gov
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and C
Trial registered· ClinicalTrials.gov
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Trial started· ClinicalTrials.gov
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
Primary completion· ClinicalTrials.gov
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
Primary completion· ClinicalTrials.gov
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Trial started· ClinicalTrials.gov
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Primary completion· ClinicalTrials.gov
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
Primary completion· ClinicalTrials.gov
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Primary completion· ClinicalTrials.gov
SMMART Adaptive Clinical Treatment (ACT) Trial
Primary completion· ClinicalTrials.gov
Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer
Label revision· FDA
WARNING: CARDIOMYOPATHY, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY WARNING: CARDIOMYOPATHY, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY See full prescribing information for complete boxed warning. Cardiomyopathy: HERCEPTIN HYLECTA can
Primary completion· ClinicalTrials.gov
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locall
Label revision· FDA
WARNING: CARDIOMYOPATHY, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY WARNING: CARDIOMYOPATHY, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY See full prescribing information for complete boxed warning. Cardiomyopathy: PHESGO administration
FDA approval (supplemental)· FDA
Sponsor: GENENTECH INC. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: GENENTECH INC. Class: Labeling.
Primary completion· ClinicalTrials.gov
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors
FDA approval (supplemental)· FDA
Sponsor: GENENTECH INC. Class: Efficacy.
FDA approval (supplemental)· FDA
Sponsor: GENENTECH INC. Class: Efficacy.
Results posted· ClinicalTrials.gov
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
FDA approval (supplemental)· FDA
Sponsor: BRISTOL-MYERS SQUIBB. Class: Labeling.
Results posted· ClinicalTrials.gov
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer
FDA approval (supplemental)· FDA
Sponsor: GENENTECH INC. Class: Labeling.
Results posted· ClinicalTrials.gov
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Sma
Results posted· ClinicalTrials.gov
ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma
FDA approval (supplemental)· FDA
Sponsor: GENENTECH INC. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: ARGENX BV. Class: Efficacy.
Results posted· ClinicalTrials.gov
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-
Results posted· ClinicalTrials.gov
Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
Trial started· ClinicalTrials.gov
Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma
Primary completion· ClinicalTrials.gov
Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients
Primary completion· ClinicalTrials.gov
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
Primary completion· ClinicalTrials.gov
Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma.
Primary completion· ClinicalTrials.gov
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
Results posted· ClinicalTrials.gov
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive
Trial registered· ClinicalTrials.gov
DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer
Trial registered· ClinicalTrials.gov
Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma
Trial registered· ClinicalTrials.gov
Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblas
Results posted· ClinicalTrials.gov
An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junctio
Results posted· ClinicalTrials.gov
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Trial started· ClinicalTrials.gov
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide
Results posted· ClinicalTrials.gov
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line T
Primary completion· ClinicalTrials.gov
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
Primary completion· ClinicalTrials.gov
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
Trial started· ClinicalTrials.gov
Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
Trial started· ClinicalTrials.gov
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Primary completion· ClinicalTrials.gov
A Trial of Ipatasertib in Combination With Atezolizumab
Primary completion· ClinicalTrials.gov
Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion
Primary completion· ClinicalTrials.gov
Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
Trial started· ClinicalTrials.gov
Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
Results posted· ClinicalTrials.gov
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
Primary completion· ClinicalTrials.gov
Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC
Results posted· ClinicalTrials.gov
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted
Trial registered· ClinicalTrials.gov
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide
Primary completion· ClinicalTrials.gov
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of
Trial started· ClinicalTrials.gov
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advance
Primary completion· ClinicalTrials.gov
Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC
Results posted· ClinicalTrials.gov
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemoth
Trial registered· ClinicalTrials.gov
Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
Trial started· ClinicalTrials.gov
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
Primary completion· ClinicalTrials.gov
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
Primary completion· ClinicalTrials.gov
Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogene
Primary completion· ClinicalTrials.gov
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
Primary completion· ClinicalTrials.gov
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
FDA approval (supplemental)· FDA
Sponsor: ARGENX BV. Class: Labeling.
Trial started· ClinicalTrials.gov
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
Primary completion· ClinicalTrials.gov
Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer
Results posted· ClinicalTrials.gov
Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
FDA approval· FDA
Sponsor: JANSSEN BIOTECH. Class: Type 5 - New Formulation or New Manufacturer.
Trial registered· ClinicalTrials.gov
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
FDA approval (supplemental)· FDA
Sponsor: JANSSEN BIOTECH. Class: Labeling.
Trial registered· ClinicalTrials.gov
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AAS
Primary completion· ClinicalTrials.gov
Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)
Primary completion· ClinicalTrials.gov
A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-sm
Primary completion· ClinicalTrials.gov
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Trial started· ClinicalTrials.gov
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
FDA approval (supplemental)· FDA
Sponsor: JANSSEN BIOTECH. Class: Efficacy.
Results posted· ClinicalTrials.gov
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
Primary completion· ClinicalTrials.gov
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Can
Trial started· ClinicalTrials.gov
Iadademstat + SBRT With Atezo in ES-SCLC
Trial started· ClinicalTrials.gov
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Trial started· ClinicalTrials.gov
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2
Trial registered· ClinicalTrials.gov
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Results posted· ClinicalTrials.gov
Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy
Trial registered· ClinicalTrials.gov
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
Trial registered· ClinicalTrials.gov
β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
Trial started· ClinicalTrials.gov
Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinom
Trial started· ClinicalTrials.gov
Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizuma
Pivotal publication· PubMed
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
2025
Primary completion· ClinicalTrials.gov
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
Primary completion· ClinicalTrials.gov
A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma
Trial started· ClinicalTrials.gov
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic
Primary completion· ClinicalTrials.gov
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
Primary completion· ClinicalTrials.gov
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
Primary completion· ClinicalTrials.gov
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
Primary completion· ClinicalTrials.gov
Atezolizumab Plus Bevacizumab With HCC and HBV Infection
Results posted· ClinicalTrials.gov
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
Primary completion· ClinicalTrials.gov
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously U
Primary completion· ClinicalTrials.gov
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
Primary completion· ClinicalTrials.gov
PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study
Primary completion· ClinicalTrials.gov
A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Can
Results posted· ClinicalTrials.gov
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With
Results posted· ClinicalTrials.gov
A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative B
Primary completion· ClinicalTrials.gov
A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Pa
Trial started· ClinicalTrials.gov
β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
Primary completion· ClinicalTrials.gov
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
Trial registered· ClinicalTrials.gov
Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)
Trial registered· ClinicalTrials.gov
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advance
Results posted· ClinicalTrials.gov
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
FDA approval· FDA
Sponsor: JANSSEN BIOTECH. Class: Type 5 - New Formulation or New Manufacturer.
Trial registered· ClinicalTrials.gov
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
Primary completion· ClinicalTrials.gov
A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lun
Trial registered· ClinicalTrials.gov
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Pra
Trial registered· ClinicalTrials.gov
Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinom
Trial registered· ClinicalTrials.gov
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
Results posted· ClinicalTrials.gov
Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC
Results posted· ClinicalTrials.gov
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Hav
Primary completion· ClinicalTrials.gov
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Anothe
Trial registered· ClinicalTrials.gov
Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizuma
Trial started· ClinicalTrials.gov
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
Trial started· ClinicalTrials.gov
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With
Trial registered· ClinicalTrials.gov
The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospec
Results posted· ClinicalTrials.gov
Atezolizumab Plus Bevacizumab in First Line NSCLC Patients
Trial registered· ClinicalTrials.gov
Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial
Trial started· ClinicalTrials.gov
Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC
Primary completion· ClinicalTrials.gov
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker
Trial started· ClinicalTrials.gov
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
Trial started· ClinicalTrials.gov
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab
FDA approval (supplemental)· FDA
Sponsor: BRISTOL-MYERS SQUIBB. Class: Efficacy.
FDA approval (supplemental)· FDA
Sponsor: GENENTECH INC. Class: Efficacy.
Results posted· ClinicalTrials.gov
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pa
Trial registered· ClinicalTrials.gov
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellu
FDA approval (supplemental)· FDA
Sponsor: JANSSEN BIOTECH. Class: Efficacy.
Trial registered· ClinicalTrials.gov
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Primary completion· ClinicalTrials.gov
EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Meta
FDA approval (supplemental)· FDA
Sponsor: GENENTECH INC. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: GENENTECH INC. Class: Labeling.
Primary completion· ClinicalTrials.gov
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
FDA approval (supplemental)· FDA
Sponsor: JANSSEN BIOTECH. Class: Labeling.
Results posted· ClinicalTrials.gov
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Canc
Trial registered· ClinicalTrials.gov
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Trial registered· ClinicalTrials.gov
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With
Trial started· ClinicalTrials.gov
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellu
Results posted· ClinicalTrials.gov
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (H
FDA approval (supplemental)· FDA
Sponsor: JANSSEN BIOTECH. Class: Efficacy.
Primary completion· ClinicalTrials.gov
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patien
Trial started· ClinicalTrials.gov
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Trial started· ClinicalTrials.gov
Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial
Primary completion· ClinicalTrials.gov
A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma
Results posted· ClinicalTrials.gov
Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell L
FDA approval (supplemental)· FDA
Sponsor: BRISTOL-MYERS SQUIBB. Class: Efficacy.
FDA approval (supplemental)· FDA
Sponsor: BRISTOL-MYERS SQUIBB. Class: Efficacy.
Results posted· ClinicalTrials.gov
Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice
Results posted· ClinicalTrials.gov
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
Results posted· ClinicalTrials.gov
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lun
Trial started· ClinicalTrials.gov
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
FDA approval (supplemental)· FDA
Sponsor: ARGENX BV. Class: Efficacy.
Primary completion· ClinicalTrials.gov
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Sma
Primary completion· ClinicalTrials.gov
DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab
Primary completion· ClinicalTrials.gov
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastr
Primary completion· ClinicalTrials.gov
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (
Primary completion· ClinicalTrials.gov
89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
Primary completion· ClinicalTrials.gov
Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial
Primary completion· ClinicalTrials.gov
A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants
Results posted· ClinicalTrials.gov
Abemaciclib With or Without Atezolizumab for mCRPC
FDA approval (supplemental)· FDA
Sponsor: GENENTECH INC. Class: Efficacy.
FDA approval (supplemental)· FDA
Sponsor: GENENTECH INC. Class: Efficacy.
Primary completion· ClinicalTrials.gov
Neoadjuvant Atezolizumab in Cutaneous Melanoma
Primary completion· ClinicalTrials.gov
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select
Primary completion· ClinicalTrials.gov
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
Primary completion· ClinicalTrials.gov
Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer
Sources
FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.